Development of population-level colon cancer pathway concordance measures and association with survival.
colonic neoplasms
guideline adherence
medical informatics computing
pathway concordance
survival rate
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 06 2022
15 06 2022
Historique:
revised:
06
12
2021
received:
24
03
2021
accepted:
04
01
2022
pubmed:
17
2
2022
medline:
20
4
2022
entrez:
16
2
2022
Statut:
ppublish
Résumé
Clinical cancer pathways help standardize healthcare delivery to optimize patient outcomes and health system costs. However, population-level measurement of concordance between standardized pathways and actual care received is lacking. Two measures of pathway concordance were developed for a simplified colon cancer pathway map for Stage II-III colon cancer patients in Ontario, Canada: a cumulative count of concordant events (CCCE) and the Levenshtein algorithm. Associations of concordance with patient survival were estimated using Cox proportional hazards models adjusted for patient characteristics and time-dependent cancer-related activities. Models were compared and the impact of including concordance scores was quantified using the likelihood ratio chi-squared test. The ability of the measures to discriminate between survivors and decedents was compared using the C-index. Normalized concordance scores were significantly associated with patient survival in models for cancer stage-a 10% increase in concordance for Stage II patients resulted in a CCCE score adjusted hazard ratio (aHR) of death of 0.93, 95% CI 0.88-0.98 and a Levenshtein score aHR of 0.64, 95% CI 0.60-0.67. A similar relationship was found for Stage III patients-a 10% increase in concordance resulted in a CCCE aHR of 0.85, 95% CI 0.81-0.88 and a Levenshtein aHR of 0.78, 95% CI, 0.74-0.81. Pathway concordance can be used as a tool for health systems to monitor deviations from established clinical pathways. The Levenshtein score better characterized differences between actual care and clinical pathways in a population, was more strongly associated with survival and demonstrated better patient discrimination.
Identifiants
pubmed: 35170750
doi: 10.1002/ijc.33964
pmc: PMC9311776
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2046-2057Informations de copyright
© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Ann Hematol. 2008 Feb;87(2):139-45
pubmed: 17938926
Int J Cancer. 2022 Jun 15;150(12):2046-2057
pubmed: 35170750
J Biomed Inform. 2013 Feb;46(1):111-27
pubmed: 23085455
Clin Med (Lond). 2004 Mar-Apr;4(2):132-5
pubmed: 15139730
Ann Intern Med. 2015 Jan 6;162(1):W1-73
pubmed: 25560730
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Clin Colorectal Cancer. 2016 Jun;15(2):179-85
pubmed: 26520019
AMIA Annu Symp Proc. 2014 Nov 14;2014:1208-17
pubmed: 25954432
J Thorac Cardiovasc Surg. 2007 Apr;133(4):865-75
pubmed: 17382616
Clin Oncol (R Coll Radiol). 2017 Jul;29(7):459-465
pubmed: 28341242
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006632
pubmed: 20238347
BMC Med. 2016 Feb 23;14:35
pubmed: 26904977
Appl Clin Inform. 2013 Mar 20;4(1):126-43
pubmed: 23650493
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Health Rep. 2012 Sep;23(3):43-51
pubmed: 23061264
Curr Oncol. 2020 Feb;27(1):e27-e33
pubmed: 32218665
Stud Health Technol Inform. 2012;180:995-9
pubmed: 22874343
J Med Screen. 2018 Sep;25(3):141-148
pubmed: 28862521
J Clin Oncol. 2013 Apr 10;31(11):1471-7
pubmed: 23478057
Can J Surg. 2009 Apr;52(2):92-7
pubmed: 19399202
BMC Med. 2010 May 27;8:31
pubmed: 20507550
Aust Health Rev. 2007 Nov;31(4):565-70
pubmed: 17973615
J Oncol Pract. 2016 Mar;12(3):261-6
pubmed: 26759491